A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
Phase II data of panobinostat in myelofibrosis demonstrates clinical activity. Panobinostat for myelofibrosis is effective in reducing spleen volume. Panobinostat requires prolonged low doses to observe clinical effect. Study of combination panobinostat and ruxolitinib for myelofibrosis is warranted.